Intranasal Ketamine Versus Intranasal Fentanyl

NCT ID: NCT04414800

Last Updated: 2020-06-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

125 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-01

Study Completion Date

2018-04-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Abstract Background: Given the inadequate control of pain in patients with injury that refer to the emergency departments, the rapid onset of action of intranasal administration in pain management, and the avoidance of administering opioid medications, the present study aimed at evaluating the effect of intranasal ketamine versus intranasal fentanyl on pain management in isolated traumatic patients Materials and Methods: The current study was performed on 125 patients that were divided into the following three groups: control group (n = 41), 1 mg/kg intranasal ketamine group (n = 40), and 1μg/kg intranasal fentanyl group (n = 44). Then pain scores, HR, RR, BP, and SaO2 were recorded at baseline, 5, 10, 15, 30, and 40 minutes after the intervention.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Trauma Pain, Acute

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control (Placebo+ Standard of Care))

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Distilled water

Ketamine + Standard of Care

Group Type ACTIVE_COMPARATOR

Ketamine

Intervention Type DRUG

1 mg/kg intranasal ketamine

Fentanyl + Standard of Care

Group Type ACTIVE_COMPARATOR

Fentanyl

Intervention Type DRUG

1μg/kg intranasal fentanyl

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Distilled water

Intervention Type DRUG

Ketamine

1 mg/kg intranasal ketamine

Intervention Type DRUG

Fentanyl

1μg/kg intranasal fentanyl

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with acute limb trauma, aged 15-65 years, with moderate to severe pain (45 mm; visual analog scale (VAS)), with a GCS score of 15, with the systolic blood pressure of lower than 180 mmHg, diastolic blood pressure of higher than 90 mmHg
* lack of pregnancy
* no history of allergy to ketamine, fentanyl (or opioids), or acetaminophen,
* no history of liver diseases,
* no acute or chronic structural or functional nasal obstruction diseases,
* no history of drug or psychiatric addiction,
* no pain medication within the past four hours,
* no history of heart disease,
* and the presentation of the written consent to participate in the study.

Exclusion Criteria

* a decrease in GCS score to less than or equal to 14,
* an elevated systolic blood pressure to higher than 180 mmHg,
* a decreased diastolic blood pressure to less than 80 mmHg,
* inability to understand the VAS pain rating system,
* symptoms of acute heart disease and respiratory depression (respiratory rate \<8 / min),
* and the patient's dissatisfaction to continue the cooperation in study
Minimum Eligible Age

15 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Isfahan University of Medical Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mehdi Nasr Isfahani

Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Al-Zahra University Hospital

Isfahan, , Iran

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Iran

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

396828

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Nebulized Fentanyl in Healthy Volunteers
NCT06281951 RECRUITING PHASE1
Sufentanil Intranasal
NCT04137198 UNKNOWN PHASE4
Nasal Fentanyl And Renal Colic
NCT01339624 COMPLETED NA